by rnossadmin | Aug 6, 2024 | Uncategorized
Tedopi® is a novel T-cell epitope-based cancer vaccine targeting five tumor-associated antigens, aimed at expanding tumor-specific T-lymphocytes in HLA-A2 cancer patients. As an off-the-shelf immunotherapy, it has been evaluated in the Phase 3 Atalante-1 trial for...
by rnossadmin | Jul 30, 2024 | Uncategorized
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA), a clinical-stage biotechnology company dedicated to developing innovative immunotherapies for cancer, has announced updated efficacy and safety results from the dose-escalation part of their Phase 1/2 study...
by rnossadmin | Jul 30, 2024 | Uncategorized
Glioblastoma (GBM) is the most common primary brain tumor in adults and is associated with a poor prognosis. The karyopherin exportin-1 (XPO1) is a nuclear export protein that plays a critical role in the transport of approximately 300 proteins from the nucleus to the...
by rnossadmin | Jun 10, 2024 | Uncategorized
Decoding the MSSG’s New Recommendations The European Medicines Agency’s Medicines Shortages Steering Group (MSSG) has developed recommendations to ensure the availability and supply of critical human medicines with identified supply chain...
by rnossadmin | Jun 10, 2024 | Uncategorized
A qualitative study involving 63 participants examined their experiences with REMS (Risk Evaluation and Mitigation Strategies) programs associated with four specific drugs: Natalizumab, Riociguat, Sodium Pxybate, and Vigabatrin. While many participants found...
